CRISPR-Cas9 is a new strategy for correcting genetics, studies have demonstrated significant restoration of cardiac dystrophin expression and improvement in cardiac pathology in different preclinical models of DMD [34, 35]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.